In investing and in life, it's rare for opportunities to be without accompanying risks, just as it's rare for clouds to be without silver linings if one looks hard enough. On that note, Iovance Biotherapeutics (NASDAQ: IOVA) is a biotech that's chock-full of upcoming opportunities for its investors, though it's also in the process of navigating a serious risk that might yet cause major disruption.

If that doesn't sound frightening to you, it might be worth considering an investment. So let's walk through three potential upsides, and one potential pitfall, to get started thinking about this stock.

The biggest near-term opportunity for Iovance is that its therapy for advanced melanoma, lifileucel, will have a shot at attaining regulatory approval by the Food and Drug Administration (FDA) on or before Feb. 24. Then, later in the year, it'll go before regulators in the E.U. and Canada.

Continue reading

Source Fool.com